AXSM | tickerfilter.com

Fundamental analysis

41%

Profitability 35%

Dept financing 39%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.38%

1 Month

-9.27%

3 Months

9.96%

6 Months

31.09%

1 Year

31.16%

2 Year

114.15%

Key data

Stock price

$164.08

P/E Ratio

0.00

DAY RANGE

$163.22 - $166.09

EPS

-$3.68

52 WEEK RANGE

$86.99 - $191.50

52 WEEK CHANGE

$31.89

MARKET CAP

9.207 B

YIELD

N/A

SHARES OUTSTANDING

51.153 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-04-2025

BETA

1.10

PUBLIC FLOAT

AVERAGE 10 VOLUME

$754,413

AVERAGE 30 VOLUME

$614,529

Company detail

CEO: Herriott Tabuteau
Region: US
Website: axsome.com
Employees: 380
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Axsome Therapeutics, Inc. engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the. treatment of smoking cessation. The firm was incorporated in 2012 and is based in New York, New York.

AXSM - Axsome Therapeutics, Inc.